Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate UpdateGlobeNewsWire • 04/10/24
Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell MalignanciesGlobeNewsWire • 04/09/24
Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6GlobeNewsWire • 04/09/24
Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead SciencesGlobeNewsWire • 04/02/24
Nurix Therapeutics is Part of a Team of International Oncology Experts Selected as Cancer Grand Challenges Awardees to Address Pediatric Cancers Using Targeted Protein Degradation (TPD)GlobeNewsWire • 03/25/24
Nurix Presents the Discovery and Chemical Structure of First-in-Class CBL-B Inhibitor NX-1607 at the American Chemical Society (ACS) MeetingGlobeNewsWire • 03/20/24
Nurix Therapeutics, Inc. (NRIX) Surges 5.1%: Is This an Indication of Further Gains?Zacks Investment Research • 02/23/24
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides a Corporate UpdateGlobeNewsWire • 02/15/24
Nurix Therapeutics Announces Publication in the Journal Science Identifying a New Class of BTK Mutations That Are Susceptible to NX-2127, a Novel BTK and IKZF1/3 DegraderGlobeNewsWire • 02/01/24
Nurix Therapeutics, Inc. (NRIX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 ReleaseZacks Investment Research • 02/01/24
Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory CLL and SLLGlobeNewsWire • 01/16/24
Nurix Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/02/24
Nurix Therapeutics Presents Positive Clinical Data from Its Novel Bruton's Tyrosine Kinase (BTK) Degrader Programs, NX-5948 and NX-2127, at the 65th American Society of Hematology (ASH) Annual MeetingGlobeNewsWire • 12/11/23
Nurix Therapeutics Announces Webcast To Review Data from Its Phase 1 Clinical Trials of BTK Degraders, NX-5948 and NX-2127, Presented at the 65th American Society of Hematology (ASH) Annual MeetingGlobeNewsWire • 12/04/23
Nurix Therapeutics Announces Presentations at the 65th American Society of Hematology (ASH) Annual MeetingGlobeNewsWire • 11/02/23
Down -34.9% in 4 Weeks, Here's Why Nurix Therapeutics, Inc. (NRIX) Looks Ripe for a TurnaroundZacks Investment Research • 10/18/23
Nurix Therapeutics Reports Third Quarter Fiscal 2023 Financial Results and Provides a Corporate UpdateGlobeNewsWire • 10/12/23
Nurix Therapeutics, Inc. (NRIX) Loses -20.27% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research • 10/05/23
Nurix Therapeutics, Inc. (NRIX) Loses -19.36% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research • 10/04/23
Nurix Therapeutics, Inc. (NRIX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 09/28/23
Nurix Therapeutics, Inc. (NRIX) Crossed Above the 50-Day Moving Average: What That Means for InvestorsZacks Investment Research • 09/20/23